Skip to main content
Top
Published in: Diabetes Therapy 3/2018

Open Access 01-06-2018 | Original Research

A Retrospective Cohort Study of Patients with Type 2 Diabetes in China: Associations of Hypoglycemia with Health Care Resource Utilization and Associated Costs

Authors: Yingping Yi, Yawei Li, Anran Hou, Yanqiu Ge, Yuan Xu, Gang Xiong, Xinlei Yang, Stephanie Ann Acevedo, Lizheng Shi, Hua Xu

Published in: Diabetes Therapy | Issue 3/2018

Login to get access

Abstract

Introduction

This study aimed to examine the associations of hypoglycemia with health care resource utilization (HCRU) and health care costs among patients with type 2 diabetes mellitus (T2DM) in China.

Methods

This retrospective cohort study was conducted with 23,680 T2DM patients >18 years old who visited the Second Affiliated Hospital of Nanchang University between 1 January 2011 and 31 December 2015. Univariate descriptive statistics were used to relate the HCRU and associated costs to patient characteristics, and regression analysis was used to examine the association between hypoglycemia and HCRU, controlling for other confounding factors.

Results

In the T2DM patients with or without insulin treatment, when compared with nonhypoglycemic patients, hypoglycemia was associated with more medical visits (all T2DM patients 19.48 vs. 10.46, insulin users 23.45 vs. 14.12) and higher diabetes-related medical costs (all T2DM patients ¥5187.54 vs. ¥3525.00, insulin users ¥6948.84 vs. ¥3401.15) and medication costs (T2DM patients ¥1349.40 vs. ¥641.92, insulin users: ¥1363.87 vs. ¥853.96). Controlling for age, gender, and Charlson comorbidity index (CCI) score, hypoglycemia and insulin intake were associated with greater health care resource utilization. As compared to nonhypoglycemic patients, hypoglycemic T2DM patients and those on insulin therapy performed more outpatient visits (proportions of hypoglycemic vs nonhypoglycemic T2DM patients performing 3+ visits: 72.69% vs. 65.49%; proportions of hypoglycemic vs nonhypoglycemic patients on insulin therapy performing 3+ visits: 78.26% vs. 71.73%) and were hospitalized more often (proportions of hypoglycemic vs nonhypoglycemic T2DM patients with 3+ admissions 75.90% vs. 50.24%; proportions of hypoglycemic vs nonhypoglycemic patients on insulin therapy with 3+ admissions: 83.19% vs. 58.51%).

Conclusion

Hypoglycemia in diabetes patients was associated with increased healthcare resource utilization and health-related expenditure, especially for patients on insulin treatment. Insulin treatment regimens should be more individualized and account for hypoglycemia risk.
Literature
1.
go back to reference World Health Organization. Global report on diabetes. Geneva: WHO; 2016. World Health Organization. Global report on diabetes. Geneva: WHO; 2016.
2.
go back to reference Valentine V, Goldman J, Shubrook JH. Rationale for initiation and titration of the basal insulin/GLP-1RA fixed-ratio combination products, IDegLira and IGlarLixi, for the management of type 2 diabetes. Diabetes Ther. 2017;8:739–52.CrossRef Valentine V, Goldman J, Shubrook JH. Rationale for initiation and titration of the basal insulin/GLP-1RA fixed-ratio combination products, IDegLira and IGlarLixi, for the management of type 2 diabetes. Diabetes Ther. 2017;8:739–52.CrossRef
3.
go back to reference Yu CG, Fu Y, Fang Y, Zhang N, Sun RX, Zhao D, Zhang BY, et al. Fighting type-2 diabetes: present and future perspectives. Curr Med Chem. 2017;24:1–17. Yu CG, Fu Y, Fang Y, Zhang N, Sun RX, Zhao D, Zhang BY, et al. Fighting type-2 diabetes: present and future perspectives. Curr Med Chem. 2017;24:1–17.
4.
go back to reference Xiong Z, Yuan L, Guo X, Lou Q, Zhao F, Shen L, Sun Z, et al. Rejection of insulin therapy among patients with type 2 diabetes in China: reasons and recommendations. Chin Med J. 2014;127:3530–6.PubMed Xiong Z, Yuan L, Guo X, Lou Q, Zhao F, Shen L, Sun Z, et al. Rejection of insulin therapy among patients with type 2 diabetes in China: reasons and recommendations. Chin Med J. 2014;127:3530–6.PubMed
5.
go back to reference Wong J, Tabet E. The introduction of insulin in type 2 diabetes mellitus. Aust Fam Physician. 2015;44:278–83.PubMed Wong J, Tabet E. The introduction of insulin in type 2 diabetes mellitus. Aust Fam Physician. 2015;44:278–83.PubMed
6.
go back to reference Wallia A, Molitch ME. Insulin therapy for type 2 diabetes mellitus. JAMA. 2014;311:2315–25.CrossRef Wallia A, Molitch ME. Insulin therapy for type 2 diabetes mellitus. JAMA. 2014;311:2315–25.CrossRef
7.
go back to reference Birkner K, Hudzik B, Gasior M. The impact of type 2 diabetes mellitus on prognosis in patients with non-ST elevation myocardial infarction. Pol J Cardio-Thorac Surg. 2017;14:127–32.CrossRef Birkner K, Hudzik B, Gasior M. The impact of type 2 diabetes mellitus on prognosis in patients with non-ST elevation myocardial infarction. Pol J Cardio-Thorac Surg. 2017;14:127–32.CrossRef
8.
go back to reference Herman ME, O’Keefe JH, Bell DSH, Schwartz SS. Insulin therapy increases cardiovascular risk in type 2 diabetes. Prog Cardiovasc Dis. 2017;60:422–34. Herman ME, O’Keefe JH, Bell DSH, Schwartz SS. Insulin therapy increases cardiovascular risk in type 2 diabetes. Prog Cardiovasc Dis. 2017;60:422–34.
9.
go back to reference Hulkower RD, Pollack RM, Zonszein J. Understanding hypoglycemia in hospitalized patients. Diabetes Manag. 2014;4:165–76.CrossRef Hulkower RD, Pollack RM, Zonszein J. Understanding hypoglycemia in hospitalized patients. Diabetes Manag. 2014;4:165–76.CrossRef
10.
go back to reference Kalra S, Mukherjee J, Ramachandran A, Saboo B, Shaikh S, Venkataraman S, Das A, et al. Hypoglycemia: the neglected complication. Indian J Endocrinol Metab. 2013;17:819.CrossRef Kalra S, Mukherjee J, Ramachandran A, Saboo B, Shaikh S, Venkataraman S, Das A, et al. Hypoglycemia: the neglected complication. Indian J Endocrinol Metab. 2013;17:819.CrossRef
11.
go back to reference Yang S-W, Park K-H, Zhou Y-J. The impact of hypoglycemia on the cardiovascular system: physiology and pathophysiology. Angiology. 2016;67:802–9.CrossRef Yang S-W, Park K-H, Zhou Y-J. The impact of hypoglycemia on the cardiovascular system: physiology and pathophysiology. Angiology. 2016;67:802–9.CrossRef
12.
go back to reference Lee AK, Lee CJ, Huang ES, Sharrett AR, Coresh J, Selvin E. Risk factors for severe hypoglycemia in black and white adults with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care. 2017;40:1661–7. Lee AK, Lee CJ, Huang ES, Sharrett AR, Coresh J, Selvin E. Risk factors for severe hypoglycemia in black and white adults with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care. 2017;40:1661–7.
13.
go back to reference Brutsaert E, Carey M, Zonszein J. The clinical impact of inpatient hypoglycemia. J Diabetes Complicat. 2014;28:565–72.CrossRef Brutsaert E, Carey M, Zonszein J. The clinical impact of inpatient hypoglycemia. J Diabetes Complicat. 2014;28:565–72.CrossRef
14.
go back to reference Green AJ, Fox KM, Grandy S. Self-reported hypoglycemia and impact on quality of life and depression among adults with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2012;96:313–8.CrossRef Green AJ, Fox KM, Grandy S. Self-reported hypoglycemia and impact on quality of life and depression among adults with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2012;96:313–8.CrossRef
15.
go back to reference Dalal MR, Kazemi M, Ye F, Xie L. Hypoglycemia after initiation of basal insulin in patients with type 2 diabetes in the United States: implications for treatment discontinuation and healthcare costs and utilization. Adv Ther. 2017;34:2083–92.CrossRef Dalal MR, Kazemi M, Ye F, Xie L. Hypoglycemia after initiation of basal insulin in patients with type 2 diabetes in the United States: implications for treatment discontinuation and healthcare costs and utilization. Adv Ther. 2017;34:2083–92.CrossRef
16.
go back to reference Lopez JMS, Bailey RA, Rupnow MFT, Annunziata K. Characterization of type 2 diabetes mellitus burden by age and ethnic groups based on a nationwide survey. Clin Ther. 2014;36:494–506.CrossRef Lopez JMS, Bailey RA, Rupnow MFT, Annunziata K. Characterization of type 2 diabetes mellitus burden by age and ethnic groups based on a nationwide survey. Clin Ther. 2014;36:494–506.CrossRef
17.
go back to reference Emral R, Pathan F, Cortes CAY, El-Hefnawy MH, Goh S-Y, Gomez AM, Mirasol R, et al. Self-reported hypoglycemia in insulin-treated patients with diabetes: results from an international survey on 7289 patients from nine countries. Diabetes Res Clin Pract. 2017;134:17–28.CrossRef Emral R, Pathan F, Cortes CAY, El-Hefnawy MH, Goh S-Y, Gomez AM, Mirasol R, et al. Self-reported hypoglycemia in insulin-treated patients with diabetes: results from an international survey on 7289 patients from nine countries. Diabetes Res Clin Pract. 2017;134:17–28.CrossRef
18.
go back to reference Polinski JM, Kim SC, Jiang D, Hassoun A, Shrank WH, Cos X, Curtis BH, et al. Geographic patterns in patient demographics and insulin use in 18 countries, a global perspective from the multinational observational study assessing insulin use: understanding the challenges associated with progression of therapy (MOSAIc). BMC Endocr Disord. 2015;15:46.CrossRef Polinski JM, Kim SC, Jiang D, Hassoun A, Shrank WH, Cos X, Curtis BH, et al. Geographic patterns in patient demographics and insulin use in 18 countries, a global perspective from the multinational observational study assessing insulin use: understanding the challenges associated with progression of therapy (MOSAIc). BMC Endocr Disord. 2015;15:46.CrossRef
19.
go back to reference Dong C, Wang T, Zhou D, Wang Y, Wang L, Lv D. Investigation and analysis of hypoglycemic drugs treatment in inpatients with type 2 diabetes mellitus in our hospital. Chin Clin Pharmacol Ther. 2017;22:87–91. Dong C, Wang T, Zhou D, Wang Y, Wang L, Lv D. Investigation and analysis of hypoglycemic drugs treatment in inpatients with type 2 diabetes mellitus in our hospital. Chin Clin Pharmacol Ther. 2017;22:87–91.
20.
go back to reference Li R, Shi L, Yang Q, Wu Z, Ruan Y, Li Y, Qi J. Glycemic control and medication compliance of type 2 diabetes in community management system in Shanghai. J Environ Occup Med. 2016;33:329–33. Li R, Shi L, Yang Q, Wu Z, Ruan Y, Li Y, Qi J. Glycemic control and medication compliance of type 2 diabetes in community management system in Shanghai. J Environ Occup Med. 2016;33:329–33.
21.
go back to reference Wang W, Ruan D, Wang X, Wei J, Tian Y. An survey on hypoglycemic agents used among patients with type 2 diabetes in Beijing Huairou Hospital. Beijing Med J. 2017;39:87–91. Wang W, Ruan D, Wang X, Wei J, Tian Y. An survey on hypoglycemic agents used among patients with type 2 diabetes in Beijing Huairou Hospital. Beijing Med J. 2017;39:87–91.
22.
go back to reference Li T, Ghang X, Li J, Wang X, Su X, Zhu L, Sun K. A three-year follow-up on patients with T2DM on drug therapy in Shihezi communities. J Pract Med. 2017;33:87–91. Li T, Ghang X, Li J, Wang X, Su X, Zhu L, Sun K. A three-year follow-up on patients with T2DM on drug therapy in Shihezi communities. J Pract Med. 2017;33:87–91.
23.
go back to reference Wu EQ, Zhou S, Yu A, Lu M, Sharma H, Gill J, Graf T. Outcomes associated with post-discharge insulin continuity in US patients with type 2 diabetes mellitus initiating insulin in the hospital. Hosp Pract. 1995;40(2012):40–8. Wu EQ, Zhou S, Yu A, Lu M, Sharma H, Gill J, Graf T. Outcomes associated with post-discharge insulin continuity in US patients with type 2 diabetes mellitus initiating insulin in the hospital. Hosp Pract. 1995;40(2012):40–8.
24.
go back to reference Scalone L, Cesana G, Furneri G, Ciampichini R, Beck-Peccoz P, Chiodini V, Mantovani LG, et al. Burden of diabetes mellitus estimated with a longitudinal population-based study using administrative databases. PloS One. 2014;9:e113741.CrossRef Scalone L, Cesana G, Furneri G, Ciampichini R, Beck-Peccoz P, Chiodini V, Mantovani LG, et al. Burden of diabetes mellitus estimated with a longitudinal population-based study using administrative databases. PloS One. 2014;9:e113741.CrossRef
25.
go back to reference Liu J, Wang R, Ganz ML, Paprocki Y, Schneider D, Weatherall J. The burden of severe hypoglycemia in type 2 diabetes. Curr Med Res Opin. 2018:34:171–7. Liu J, Wang R, Ganz ML, Paprocki Y, Schneider D, Weatherall J. The burden of severe hypoglycemia in type 2 diabetes. Curr Med Res Opin. 2018:34:171–7.
26.
go back to reference Heller SR, Frier BM, Herslov ML, Gundgaard J, Gough SCL. Severe hypoglycaemia in adults with insulin-treated diabetes: impact on healthcare resources. Diabet Med. 2016;33:471–7.CrossRef Heller SR, Frier BM, Herslov ML, Gundgaard J, Gough SCL. Severe hypoglycaemia in adults with insulin-treated diabetes: impact on healthcare resources. Diabet Med. 2016;33:471–7.CrossRef
27.
go back to reference Foos V, Varol N, Curtis BH, Boye KS, Grant D, Palmer JL, McEwan P. Economic impact of severe and non-severe hypoglycemia in patients with type 1 and type 2 diabetes in the United States. J Med Econ. 2015;18:420–32.CrossRef Foos V, Varol N, Curtis BH, Boye KS, Grant D, Palmer JL, McEwan P. Economic impact of severe and non-severe hypoglycemia in patients with type 1 and type 2 diabetes in the United States. J Med Econ. 2015;18:420–32.CrossRef
28.
go back to reference Williams SA, Shi L, Brenneman SK, Johnson JC, Wegner JC, Fonseca V. The burden of hypoglycemia on healthcare utilization, costs, and quality of life among type 2 diabetes mellitus patients. J Diabetes Complicat. 2012;26:399–406.CrossRef Williams SA, Shi L, Brenneman SK, Johnson JC, Wegner JC, Fonseca V. The burden of hypoglycemia on healthcare utilization, costs, and quality of life among type 2 diabetes mellitus patients. J Diabetes Complicat. 2012;26:399–406.CrossRef
29.
go back to reference Kong APS, Chan JCN. Hypoglycemia and comorbidities in type 2 diabetes. Curr Diabetes Rep. 2015;15(10):80.CrossRef Kong APS, Chan JCN. Hypoglycemia and comorbidities in type 2 diabetes. Curr Diabetes Rep. 2015;15(10):80.CrossRef
30.
go back to reference Bremer JP, Jauch-Chara K, Hallschmid M, Schmid S, Schultes B. Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes. Diabetes Care. 2009;32:1513–7.CrossRef Bremer JP, Jauch-Chara K, Hallschmid M, Schmid S, Schultes B. Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes. Diabetes Care. 2009;32:1513–7.CrossRef
31.
go back to reference Chen Y, Wang J, Wang L-J, Lin H, Huang P-J. Effect of different blood glucose intervention plans on elderly people with type 2 diabetes mellitus combined with dementia. Eur Rev Med Pharmacol Sci. 2017;21:2702–7.PubMed Chen Y, Wang J, Wang L-J, Lin H, Huang P-J. Effect of different blood glucose intervention plans on elderly people with type 2 diabetes mellitus combined with dementia. Eur Rev Med Pharmacol Sci. 2017;21:2702–7.PubMed
32.
go back to reference Hirsch IB. Professional flash continuous glucose monitoring as a supplement to A1C in primary care. Postgrad Med 2017:129:781–90. Hirsch IB. Professional flash continuous glucose monitoring as a supplement to A1C in primary care. Postgrad Med 2017:129:781–90.
33.
go back to reference Ishikawa T, Koshizaka M, Maezawa Y, Takemoto M, Tokuyama Y, Saito T, Yokote K. Continuous glucose monitoring reveals hypoglycemia risk in elderly patients with type 2 diabetes mellitus. J Diabetes Investig. 2018;9:69–74. Ishikawa T, Koshizaka M, Maezawa Y, Takemoto M, Tokuyama Y, Saito T, Yokote K. Continuous glucose monitoring reveals hypoglycemia risk in elderly patients with type 2 diabetes mellitus. J Diabetes Investig. 2018;9:69–74.
34.
go back to reference Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger P-M. Insulin adherence behaviours and barriers in the multinational global attitudes of patients and physicians in insulin therapy study. Diabet Med. 2012;29:682–9.CrossRef Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger P-M. Insulin adherence behaviours and barriers in the multinational global attitudes of patients and physicians in insulin therapy study. Diabet Med. 2012;29:682–9.CrossRef
35.
go back to reference Sambamoorthi U, Garg R, Deb A, Fan T, Boss A. Persistence with rapid-acting insulin and its association with A1C level and severe hypoglycemia among elderly patients with type 2 diabetes. Curr Med Res Opin. 2017;33:1309–16.CrossRef Sambamoorthi U, Garg R, Deb A, Fan T, Boss A. Persistence with rapid-acting insulin and its association with A1C level and severe hypoglycemia among elderly patients with type 2 diabetes. Curr Med Res Opin. 2017;33:1309–16.CrossRef
36.
go back to reference Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger P-M. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy Study. Diabet Med. 2012;29:682–9. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger P-M. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy Study. Diabet Med. 2012;29:682–9.
37.
go back to reference Wit HM, Vervoort GMM, de Galan BE, de Tack CJ. A cost-controlling treatment strategy of adding liraglutide to insulin in type 2 diabetes. Neth J Med. 2017;75:272–80.PubMed Wit HM, Vervoort GMM, de Galan BE, de Tack CJ. A cost-controlling treatment strategy of adding liraglutide to insulin in type 2 diabetes. Neth J Med. 2017;75:272–80.PubMed
38.
go back to reference Lane WS, Weatherall J, Gundgaard J, Pollock RF. Insulin degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US: a budget impact analysis with rebate tables. J Med Econ 2018:21:144–51. Lane WS, Weatherall J, Gundgaard J, Pollock RF. Insulin degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US: a budget impact analysis with rebate tables. J Med Econ 2018:21:144–51.
39.
go back to reference Mu YM, Guo LX, Li L, Li YM, Xu XJ, Li QM, Pan CY. The efficacy and safety of insulin degludec versus insulin glargine in insulin-naive subjects with type 2 diabetes: results of a Chinese cohort from a multinational randomized controlled trial. Chin J Intern Med. 2017;56:660–6. Mu YM, Guo LX, Li L, Li YM, Xu XJ, Li QM, Pan CY. The efficacy and safety of insulin degludec versus insulin glargine in insulin-naive subjects with type 2 diabetes: results of a Chinese cohort from a multinational randomized controlled trial. Chin J Intern Med. 2017;56:660–6.
40.
go back to reference Min SH, Yoon JH, Hahn S, Cho YM. Efficacy and safety of combination therapy with an alpha-glucosidase inhibitor and a dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: a systematic review with meta-analysis. J Diabet Investig. 2017. https://doi.org/10.1111/jdi.12754. Min SH, Yoon JH, Hahn S, Cho YM. Efficacy and safety of combination therapy with an alpha-glucosidase inhibitor and a dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: a systematic review with meta-analysis. J Diabet Investig. 2017. https://​doi.​org/​10.​1111/​jdi.​12754.
41.
go back to reference Zhao L, Sun T, Wang L. Chitosan oligosaccharide improves the therapeutic efficacy of sitagliptin for the therapy of Chinese elderly patients with type 2 diabetes mellitus. Ther Clin Risk Manag. 2017;13:739–50.CrossRef Zhao L, Sun T, Wang L. Chitosan oligosaccharide improves the therapeutic efficacy of sitagliptin for the therapy of Chinese elderly patients with type 2 diabetes mellitus. Ther Clin Risk Manag. 2017;13:739–50.CrossRef
Metadata
Title
A Retrospective Cohort Study of Patients with Type 2 Diabetes in China: Associations of Hypoglycemia with Health Care Resource Utilization and Associated Costs
Authors
Yingping Yi
Yawei Li
Anran Hou
Yanqiu Ge
Yuan Xu
Gang Xiong
Xinlei Yang
Stephanie Ann Acevedo
Lizheng Shi
Hua Xu
Publication date
01-06-2018
Publisher
Springer Healthcare
Published in
Diabetes Therapy / Issue 3/2018
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI
https://doi.org/10.1007/s13300-018-0409-1

Other articles of this Issue 3/2018

Diabetes Therapy 3/2018 Go to the issue